New PET imaging study aims to sharpen tumor detection

NCT ID NCT07664410

Recruiting now Knowledge-focused Sponsor: University Hospital, Essen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participants will have their imaging data and medical records analyzed, but no experimental treatment is given.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: theranostic PET tracers (imaging agents used for both diagnosis and therapy planning)
What this could lead to: If successful, this could improve how doctors detect tumors and plan treatments using advanced PET imaging.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly benefit participants. Results may not change current practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID MALIGNANCIES

Contacts and locations

Locations

University Hospital Essen
RECRUITING

Essen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.